-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target

Benzinga·11/04/2026 16:59:28
Listen to the news
RBC Capital analyst Luca Issi reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and maintains $155 price target.